Background: Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine.
Objective And Results: Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle.
Conclusion: Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521349 | PMC |
| http://dx.doi.org/10.1177/13524585211022719 | DOI Listing |
Publication Analysis
Top Keywords
multiple sclerosis
8
cladribine treatment
8
autoimmune glomerulonephritis
4
glomerulonephritis multiple
4
sclerosis patient
4
patient cladribine
4
treatment background
4
background oral
4
oral cladribine
4
cladribine approved
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!